Background
PD-L1 expression and prognosis value in gliomas
Author (year) | Sample size | WHO grade | Assay | Material | Tissue samples | Antibody | Staining patterns | Cut-offa
| Rate (%)b
|
---|---|---|---|---|---|---|---|---|---|
Wintterle et al. (2003) | 10 | III + IV | IHC | Frozen sections | Full slides | 5H1 | NM | Presence of PD-L1 staining | 100 |
Wilmotte et al. (2005) | 54 | II–IV | IHC | Frozen sections | Full slides | MIH1 | Membranous/cytoplasm | Presence of PD-L1 staining | 85.2 |
Yao et al. (2009) | 48 | I–IV | IHC | Frozen sections | Full slides | MIH1 (Ebioscience) | Membranous/cytoplasm | NM | NM |
I–IV | WB | Fresh tissues | Full slides | Anti-PD-L1 (R&D Systems) | NM | NM | 75.0 | ||
Avril et al. (2010) | 20 | IV | IHC | PE | NM | Anti-PD-L1 (Clinisciences) | NM | >25% | 45.0 |
Liu et al. (2013) | 17 | III + IV | IFC | Frozen sections | NM | Anti-human PD-L1 (558065; BD PharMingen) | NM | Presence of PD-L1 staining | 76.5 |
Berghoff et al. (2014) | 135 | IV | IHC | PE | Full slides | 5H1 | Membranous | >5% | 34.8 |
Diffuse/fibrillary | Presence of PD-L1 staining | 82.9 | |||||||
Nduom et al. (2015) | 99 | IV | IHC | PE | Tissue microarray | EPR1161(2) (Abcam) | Membranous | ≥1% | 60.6 |
Zeng et al. (2016) | 229 | I–IV | IHC | PE | Tissue microarrays | Rabbit anti-PD-L1 | Membranous/cytoplasm | >5% | 51.1 |
Garber et al. (2016) | 345 | I–IV | IHC | PE | Full slides | SP142 (Spring Biosciences) | Membrane | >5% | 6.1 |
Pooled data | 957 | 44.7 |
PD-L1-mediated immunosuppressive and upregulation mechanisms in glioma
Glioma treatment using a PD-1/PD-L1 blocking antibody
Combination therapy strategy and preclinical research
Clinical studies of PD-1/PD-L1 targeting in glioma
Clinical trials
Target | Clinical trial identifier | Blockade agent | Phase | Patient population | Design | Study start date | Current stage |
---|---|---|---|---|---|---|---|
PD-1 | NCT02550249 | Nivolumab | II | Primary and recurrent GBM | Preoperative neoadjuvant | June 2015 | Recruiting participants |
NCT02423343 | Nivolumab | I/II | Recurrent or refractory NSCLC HCC GBM | Combination with galunisertib | October 2015 | Recruiting participants | |
NCT02017717 (CheckMate 143) | Nivolumab | III | Recurrent GBM | Alone or in combination with the IPI Compared to bevacizumab | January 2014 | Ongoing | |
NCT02311920 | Nivolumab | I | Primary GBM | IPI and/or NIVO in combination with temozolomide | April 2015 | Recruiting participants | |
NCT02337491 | Pembrolizumab | II | Recurrent GBM | With or without bevacizumab | February 2015 | Ongoing | |
NCT02311582 | Pembrolizumab | I/II | Recurrent GBM | Combination with MRI-guided laser ablation | August 2015 | Recruiting participants | |
NCT01952769 | Pidilizumab | I/II | DIPG and recurrent GBM | Alone | February 2014 | Recruiting participants | |
PD-L1 | NCT02336165 | MEDI4736 | II | Primary and recurrent GBM | Combination with radiotherapy and bevacizumab | February 2015 | Recruiting participants |
NCT01375842 | MPDL3280A | I | Solid tumors (include GBM) | Alone | June 2011 | Recruiting participants |